In the final part of our ACR 2020 highlights series, Peter C Taylor (University of Oxford, Oxford, UK) reviews the results from an observational multicentric study investigating the efficacy and safety of a second jakinib in patients who failed to respond, or had side effects, from a previous jakinib.
The abstract entitled ‘Efficacy and Safety of Switching Jakinibs in Rheumatoid Arthritis’ was presented at ACR Convergence 2020.
Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of virtual ACR Convergence 2020.
Share this Video
Related Videos In Rheumatoid Arthritis
Axel Finckh, EULAR 2022: Findings from the “JAK-pot” Study
The “JAK-pot” study compared the safety of JAK inhibitors (JAKis) to other biologic agents in the treatment of patients with rheumatoid arthritis (RA). touchIMMUNOLOGY were delighted to speak with Prof. Axel Finckh (University of Geneva, Geneva, Switzerland) to discuss real world safety and tolerability of JAKis and treatment discontinuation for JAKis compared to other treatments […]
Hiroya Tamai, EULAR 2022: MIRACLE Study of Adalimumab with Low and High Dose-methotrexate in RA
The MIRACLE study investigated the optimal dose of methotrexate when used in combination with adalimumab for rheumatoid arthritis. touchIMMUNOLOGY caught up with Dr. Hiroya Tamai (Keio University School of Medicine, Tokyo, Japan) to discuss the findings from this study and the conclusions of the investigators. The abstract ‘Efficacy and safety of adalimumab with low and […]
Maarten Boers, EULAR 2022: the GLORIA Trial – Investigating Prednisolone in Rheumatoid Arthritis
touchIMMUNOLOGY were delighted to speak with Prof. Maarten Boers (Amsterdam University Medical Center, Amsterdam, The Netherlands) to discuss the GLORIA trial, investigating the benefits and harms of long term add-on low dose prednisolone in rheumatoid arthritis. The abstract ‘Favorable balance of benefit and harm of long-term, low dose prednisolone added to standard treatment in rheumatoid […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!